Literature DB >> 12554522

Palliative radiotherapy in children with neuroblastoma.

Arnold C Paulino1.   

Abstract

Limited information is available regarding the efficacy of external beam radiation therapy in the palliation of metastatic disease from neuroblastoma. From 1960 to 2000, 29 children with 53 metastatic sites received palliative radiotherapy. There were 26 soft tissue (group I), 19 bone (group II), 5 brain (group III), and 3 hepatic (group IV) treated sites. Median radiotherapy doses for groups I, II, III, and IV sites were 2000, 2000, 2400, and 450 cGy, respectively. For group I sites, complete response was complete disappearance of mass, partial response was > or =50% resolution of mass, no response was <50% resolution or < or =25% progression of mass, and progressive disease was >25% progression of mass. For group II sites, complete response was complete pain relief without medication, partial response was > or =50% pain relief with or without medication, no response was <50% change in pain with medication, and progressive disease was increase in pain and/or medication. Median survival was 2.5 months after palliative radiotherapy. For group I sites, complete response was seen in 1 (4%) while partial response was documented in 19 (73%). Duration of response was until death in 18 responders (90%); 2 patients relapsed with an increasing soft tissue mass at 5 months and 1 year after palliative radiotherapy. For group II sites, complete response was seen in 8 (42%) while partial response was documented in 7 (37%). Duration of response was until death in 14 responders (93%); 1 patient had relapse of pain 1 year after palliative radiotherapy. For the 5 group III children, the median survival was 2.5 months with a range of 2 days to 13 months. Four children had neurological improvement after cranial radiotherapy; one patient progressed and died secondary to neurological compromise 2 days after radiotherapy. For the 3 group IV sites, 2 had improvement in respiratory status after radiotherapy, whereas 1 progressed despite doxorubicin, cyclophosphamide, and radiation. The only patient who survived had a stage IV-S neuroblastoma with liver metastases and is alive 13 years after hepatic irradiation. Radiotherapy is an effective treatment for palliation of symptomatic metastatic disease in children with neuroblastoma.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12554522     DOI: 10.1080/0880010390158702

Source DB:  PubMed          Journal:  Pediatr Hematol Oncol        ISSN: 0888-0018            Impact factor:   1.969


  6 in total

1.  Radiation therapy as part of local control of metastatic neuroblastoma: the St Jude Children's Research Hospital experience.

Authors:  Jared R Robbins; Matthew J Krasin; Atmaram S Pai Panandiker; Amy Watkins; Jianrong Wu; Victor M Santana; Wayne L Furman; Andrew M Davidoff; Lisa M McGregor
Journal:  J Pediatr Surg       Date:  2010-04       Impact factor: 2.545

2.  Outcomes After Radiation Therapy to Metastatic Sites in Patients With Stage 4 Neuroblastoma.

Authors:  Shravan Kandula; Roshan S Prabhu; Ronica Nanda; Jeffrey M Switchenko; Thomas Cash; Muna Qayed; Howard Katzenstein; Natia Esiashvili
Journal:  J Pediatr Hematol Oncol       Date:  2015-04       Impact factor: 1.289

3.  Knowledge and utilization of palliative radiotherapy by pediatric oncologists.

Authors:  T L Tucker; R S Samant; E J Fitzgibbon
Journal:  Curr Oncol       Date:  2010-02       Impact factor: 3.677

4.  Stereotactic Body Radiation Therapy for Metastatic and Recurrent Solid Tumors in Children and Young Adults.

Authors:  Christopher L Tinkle; Charu Singh; Shane Lloyd; Yian Guo; Yimei Li; Alberto S Pappo; Steven G DuBois; John T Lucas; Daphne A Haas-Kogan; Stephanie A Terezakis; Steve E Braunstein; Matthew J Krasin
Journal:  Int J Radiat Oncol Biol Phys       Date:  2020-11-28       Impact factor: 7.038

5.  The SK-N-AS human neuroblastoma cell line develops osteolytic bone metastases with increased angiogenesis and COX-2 expression.

Authors:  Takahiro Tsutsumimoto; Paul Williams; Toshiyuki Yoneda
Journal:  J Bone Oncol       Date:  2014-10-31       Impact factor: 4.072

6.  SIOP-PODC adapted risk stratification and treatment guidelines: Recommendations for neuroblastoma in low- and middle-income settings.

Authors:  Nehal S Parikh; Scott C Howard; Guillermo Chantada; Trijn Israels; Mohammed Khattab; Patricia Alcasabas; Catherine G Lam; Lawrence Faulkner; Julie R Park; Wendy B London; Katherine K Matthay
Journal:  Pediatr Blood Cancer       Date:  2015-03-21       Impact factor: 3.167

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.